Research programme: next-generation interferon alpha and beta therapies - Maxygen/Roche
Alternative Names: MAXY-24; Next-generation interferon alpha and beta therapies research programme - Maxygen/RocheLatest Information Update: 10 Jun 2013
At a glance
- Originator Maxygen
- Developer Maxygen; Roche
- Class Interferons
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis B; Hepatitis C
Most Recent Events
- 26 Nov 2007 Discontinued - Preclinical for Hepatitis B in USA (unspecified route)
- 26 Nov 2007 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)
- 28 May 2003 Preclinical trials in Hepatitis B treatment in USA (unspecified route)